DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

Loss of DAB2IP, a novel tumor suppressor gene, is associated with the high risk of aggressive prostate cancer (PCa). Previously, we reported that DAB2IP modulated androgen receptor activation in the development of castration-resistant PCa; however, its direct action on the failure of androgen depriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, J, Ning, Z, Wang, B, Yun, E-J, Zhang, T, Pong, R-C, Fazli, L, Gleave, M, Zeng, J, Fan, J, Wang, X, Li, L, Hsieh, J-T, He, D, Wu, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399177/
https://www.ncbi.nlm.nih.gov/pubmed/26512963
http://dx.doi.org/10.1038/cddis.2015.289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399177/
https://www.ncbi.nlm.nih.gov/pubmed/26512963
http://dx.doi.org/10.1038/cddis.2015.289

Ejemplares similares